BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32344898)

  • 41. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
    Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
    World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma.
    Jin Y; Liang ZY; Zhou WX; Zhou L
    Cancer Biomark; 2020; 27(3):285-293. PubMed ID: 31640087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Harada Y; Kazama S; Morikawa T; Emoto S; Murono K; Kaneko M; Sasaki K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Hata K; Nozawa H; Ishihara S; Watanabe T
    APMIS; 2018 Jun; 126(6):486-493. PubMed ID: 29924454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
    Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
    Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
    Fernández-Aceñero MJ; Cortés D; Gómez del Pulgar T; Cebrián A; Estrada L; Martínez-Useros J; Celdrán A; García-Foncillas J; Pastor C
    Pathol Oncol Res; 2016 Apr; 22(2):377-83. PubMed ID: 26577686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.
    Shioya M; Takahashi T; Ishikawa H; Sakurai H; Ebara T; Suzuki Y; Saitoh J; Ohno T; Asao T; Kuwano H; Nakano T
    J Radiat Res; 2011; 52(6):821-7. PubMed ID: 22104271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.
    Sternlicht MD; Dunning AM; Moore DH; Pharoah PD; Ginzinger DG; Chin K; Gray JW; Waldman FM; Ponder BA; Werb Z
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2107-14. PubMed ID: 17119035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.
    Rödel F; Hoffmann J; Grabenbauer GG; Papadopoulos T; Weiss C; Günther K; Schick C; Sauer R; Rödel C
    Strahlenther Onkol; 2002 Aug; 178(8):426-35. PubMed ID: 12240548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time.
    Shabo I; Olsson H; Sun XF; Svanvik J
    Int J Cancer; 2009 Oct; 125(8):1826-31. PubMed ID: 19582880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
    Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
    Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TRPM7 deficiency suppresses cell proliferation, migration, and invasion in human colorectal cancer via regulation of epithelial-mesenchymal transition.
    Su F; Wang BF; Zhang T; Hou XM; Feng MH
    Cancer Biomark; 2019; 26(4):451-460. PubMed ID: 31640089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis.
    Yao YF; Du CZ; Chen N; Chen P; Gu J
    Dis Colon Rectum; 2014 May; 57(5):602-7. PubMed ID: 24819100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome.
    Moore HG; Shia J; Klimstra DS; Ruo L; Mazumdar M; Schwartz GK; Minsky BD; Saltz L; Guillem JG
    Ann Surg Oncol; 2004 Nov; 11(11):955-61. PubMed ID: 15525823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer.
    Bhangu A; Wood G; Brown G; Darzi A; Tekkis P; Goldin R
    Colorectal Dis; 2014 Apr; 16(4):O133-43. PubMed ID: 24617665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastatic role of mammalian target of rapamycin signaling activation by chemoradiotherapy in advanced rectal cancer.
    Shiratori H; Kawai K; Okada M; Nozawa H; Hata K; Tanaka T; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Murono K; Emoto S; Ishii H; Sonoda H; Ushiku T; Ishihara S
    Cancer Sci; 2020 Apr; 111(4):1291-1302. PubMed ID: 31997546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy in rectal cancer.
    Rödel F; Capalbo G; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):846-52. PubMed ID: 19131184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.